The Anti-Inflammatory Benefit of Statins for Chronic Obstructive Pulmonary Disease (COPD): Review Article
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is characterized by progressive, minimally reversible airflow limitation and systemic inflammation. Over the last 5 years, there have been abundant studies proving the benefit of statin in COPD as an anti-inflammatory agent. So far, statin is mostly utilized in cardiology due to its effects of cholesterol reduction, immune system modulation, and anti oxidant. In point of fact, the effects of statin have proven to be advantageous when administered to COPD patients. The aim of this review is to examine the pharmacological mechanism of statins as anti-inflammatory drugs so that they can be considered as therapy in COPD.
References
Anonym. COPD: Definition. Available from http://www.who.int/respiratory/copd/definition/en/. 2018. Accessed July 14, 2018.
Han M., Dransfield M., Martinez F. Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging. 2018. Available from https://www.uptodate.com/contents/chronic-obstructive-pulmonary-disease-definition-clinical-manifestations-diagnosis-and-staging, Accessed July 14, 2018
GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017 ; Sep;5(9):691-706.
Centers for Disease Control and Prevention (CDC). Chronic obstructive pulmonary disease among adults--United States, 2011, MMWR Morb Mortal Wkly Rep. 2012 ; Nov 23;61(46):938-43.
Leem AY., Park B., Kim YS., Jung JY., Sungho W. Incidence and risk of chronic obstructive pulmonary disease in a Korean community-based cohort. International Journal of COPD, 2018 :13 509–517
World Health Organization. Chronic obstructive pulmonary disease (COPD). Geneva, Switzerland: WHO; 2015. Available from: http:// www.who.int/respiratory/copd/en/. Accessed July 14, 2018.
Arialdi MM., Murphy SL., Xu J., and Kochanek, Kenneth DK. Deaths: Final Data for 2008. National Vital Statistics Reports. 2011 ; Vol. 59, No. 10, December 7,
Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2018. Global Strategy for the Diagnosis, Management and Prevention of chronic obstructive pulmonary disease: 2018 Report, www.goldcopd.org, Accessed July 14, 2018.
Boka, K. Emphysema, Available from https://emedicine.medscape.com/article/298283-overview. 2016 ; Accessed July 14, 2018.
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (2018 update), Available from www.ginasthma.org. 2018 ; Accessed March 15, 2018).
Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol July 2016
Barnes PJ. Mechanisms in COPD Differences From Asthma. Chest / 117/2/ February, 2000 Supplement
Agusti A. Global Strategy For The Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2018 Report)., Global Initiative for Chronic Obstructive Lung Disease.
Young RP., Hopkins RJ., Eaton TE. Pharmacological actions of Statin: Potential utility in COPD. Eur Respir. Rev. 2009 ; 18, 222-232
Maneechotesuwan K., Wongkajornsilp A., Adcock IM., Barnes PJ. Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD. Chest. 2015 ; 148(5):1164-1176.
Mroz RM., Lisowski P., Tycinska A., Bierla J., Trzeciak PZ., Minarowski L., Milewski R., Lisowska A., Boros P., Sobkowicz B., Duszewska AM., Chyczewska E., Musial WJ., MacNee W. Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study. J Physiol Pharmacol. 2015 ; 66(1):111-128..
Zeki AA., Franzi L., Last J., Kenyon NJ. Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med. 2009 ;180(8):731-740.
Gazzerro P. Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer. Pharmacol Rev. 2012 ; 64:102–146, 2012
Stancu C., Sima A. Statins: mechanism of action and effect. J.Cell.Mol.Med.. 2001 ; Vol 5, No 4, pp. 378-387
Takahashi S., Nakamura H., Furuuchi M. Simvastatin suppresses the development of elastase-induced emphysema in mice (abstract). Proc Am Thor Soc. 2005 ; 2:A135
Arnaud C., Burger F., Steffens S., Veillard NR., Nguyen TH., Trono D., Mach F. Statins reduce interleukin-6- induced c-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol. 2005; 25: 1231–1236.
Ito T., Ikeda U., Yamamoto K., Shimada K. Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells. Chest. 2007 ; 132: 1409.
Murphy DM., Forrest IA., Corris PA., Johnson GE., Small T., Jones, D., Fisher, AJ., Egan, JJ., Cawston, TE., Ward, C., Lordan, JL., 2008. Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients, Am J Physiol Lung Cell Mol Physiol 2008; 294: L592–L599.
Lee JH., Lee DS., Kim EK., Choe KH., Oh YM., Shim TS., Kim SE., Lee YS., Lee SD. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005 ; 172: 987–993
Rikitake Y., Kawashima S., Takeshita S., Yamashita T., Azumi H., Yasuhara M., Nishi H., Inoue N., Yokoyama M. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001 ; 154: 87–96.
Wei CY., Huang KC., Chou YH., Hsieh PF., Lin KH., Lin WW. The role of Rho-associated kinase in differential regulation by statins of IL-1B and LPS mediated NFkB activation and iNOS gene expression in vascular smooth muscle cells. Mol Pharmacol. 2006 ; 69: 960–967.
Iwata A., Shirai R., Ishii H., Kushima H., Otani S., Hashinaga K., Umeki K., Kishi K., Tokimatsu I., Hiramatsu K., Kadota J. Anti-inflammatory effect of statins on human bronchial epithelial cells. American Thoracic Society. 2009; San Diego 2009. A3735
Hothersall E., McSharry C., Thomson NC., Potential therapeutic role for statins in respiratory disease. Thorax. 2006 ; 61:729–734.
Wagner AH., Kohler T., Ruckschloss U., Just I., Hecker M. Improvement of nitric oxide dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation,. Arterioscler Thromb Vasc Biol. 2000 ; 20:61–9
Ehrenstein MR., Jury EC., Mauri C. Statins for atherosclerosis – as good as it gets?, N Engl J Med. 2005 ; 352:73–5.
Nath N., Giri S., Prasad R., Singh AK., Sing, I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol. 2004 ;172:1273–86.
Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator, Nat Med. 2000 ; 6:1399–402.
Mach F. Statins as novel immunomodulators: from cell to potential clinical benefit. Thromb Haemost. 2003 ; 90:607–10.
Hakamada-Taguchi R., Uehara Y., Kuribayashi K., Numabe A., Saito K., Negoro H., Fujita T., Toyo-oka T., Kato T., 2003. Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res. 2003 ; 93:948–56
Lawes C., Thornley S., Young R., Hopkins R., Marshall R., Chan WC., Jackson G. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J ; 2012;21(1):35–40.
Wang M., Lo Y., Tsai C., Chang L., Malone D., Chu C., Liou JT. Statin use and risk of COPD exacerbation requiring hospitalization, Am J Med. 2013 ;126(7):598–606
Ingebrigtsen T., Marott J., Nordestgaard B., Lange P., Hallas J., Vestbo J. 2015. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015 ; 70(1):33
Cao C., Wu Y., Xu Z., Lv D., Zhang C., Lai T., Li W., Shen H. The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: a systematic review and meta analysis of observational research. Sci. Rep. 2015 ; 5, 16461
Zhang W., Zhang Y., Li CW., Jones P., Wang C., Fan Y. Effect of Statins on COPD: A Meta-Analysis of Randomized Controlled Trials. Chest. 2017 ; Dec;152(6):1159-1168.
